BCL2 and B-cell non-Hodgkin lymphoma: Among them, DT2216 has entered the clinical stage and with the best prospects, which targets B-cell lymphoma/leukemia-xL (Bcl-xL) to the VHL E3 ligase for degradation, thereby inhibiting the anti-apoptotic function of the B-cell lymphoma/leukemia-2 (Bcl-2) family.